Table 1 Clinical information and laboratory data of the cohort

Number of patients

25

17

14

9

Clinical information

Age

47 (26–65)

55 (33–62)

54 (32–67)

49 (37–61)

0.659

Gender

0.648

Female, n (%)

18 (75)

9 (53)

8 (57)

6 (67)

Male, n (%)

7 (25)

8 (47)

6 (43)

3 (33)

Onset time (Days)

4 (2–7)

6 (3–10)

2 (2–5)

5 (2–9)

0.306

Onset to plasma therapy (Days)

7 (5–10)

11 (5–15)

5 (4–8)

11 (4–14)

0.319

Neurological symptoms to plasma therapy (Days)

6 (4–9)

11 (4–15)

5 (4–8)

11 (4–14)

0.319

Pentad, n (%)

7 (28)

7 (41)

3 (21)

3 (33)

0.526

LOS (Days)

11 (5–16)

3 (1–9)

12 (5–17)

4 (2–18)

0.206

PLASMIC score (6–7), n (%)

20 (83)

13 (93)

13 (93)

9 (100)

0.412

Comorbidities

Diabetes, n (%)

3 (12)

0 (0)

3 (21)

0 (0)

0.136

Hypertension, n (%)

3 (12)

2 (11.8)

3 (21)

2 (22)

0.964

Connective tissue disease, n (%)

3 (12)

2 (12)

1 (7)

2 (22)

0.295

Cardiovascular disease, n (%)

1 (4)

0 (0)

1 (7)

0 (0)

0.412

Infection, n (%)

5 (20)

5 (29)

3 (21)

3 (33)

0.526

Treatment

Drugs preuse, n (%)

11 (44)

12 (71)

7 (50)

4 (44)

0.795

Number of plasma exchanges

4 (2–5)

1 (0–4)

4 (2–5)

2 (5–9)

0.485

Laboratory data

Pos ANA, n (%)

11 (55)

7 (50)

5 (42)

5 (56)

0.528

WBC (×10⁹/L)

9.1 (6.4–9.4)

8.0 (6.4–12.4)

9.1 (6.4–9.3)

6.9 (5.2–8.9)

0.186

RBC (×10¹²/L)

2.64 (2.21–2.95)

2.09 (1.79–2.57)

2.81 (2.13–3.01)

2.43 (1.95–2.95)

0.450

Hb (g/L)

82 (69–90)

69 (57–82)

84 (70–91)

73 (63–89)

0.488

PLT (×10⁹/L)

14 (8–24)

8 (7–28)

13 (9–19)

7 (4–12)

0.043

ALT(U/L)

23 (18–35)

27 (19–38)

21 (16–36)

28 (19–38)

0.508

AST(U/L)

50 (34–64)

60 (53–94)

45 (33–63)

57 (52–65)

0.130

IBIL(µmol/L)

30 (21–46)

45 (36–57)

30 (17–47)

45 (38–68)

0.068

Glucose (mmol/L)

6.6 (5.5–8.1)

9.8 (7.1–12.1)

7.5 (5.7–8.4)

9.7 (6.4–11.8)

0.027

LDH (U/L)

887 (563–1300)

1351(1082–1711)

956 (616–1310)

1189 (1026–1387)

0.073